Focused On-demand Library for H/ACA ribonucleoprotein complex subunit 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NPE3

UPID:

NOP10_HUMAN

Alternative names:

Nucleolar protein 10; Nucleolar protein family A member 3; snoRNP protein NOP10

Alternative UPACC:

Q9NPE3

Background:

H/ACA ribonucleoprotein complex subunit 3, also known as Nucleolar protein 10, plays a crucial role in ribosome biogenesis and telomere maintenance. It is a part of the H/ACA small nucleolar ribonucleoprotein (snoRNP) complex, facilitating the pseudouridylation of rRNA, which stabilizes the conformation of rRNAs. Additionally, it aids in the processing or intranuclear trafficking of TERC, essential for telomerase activity.

Therapeutic significance:

The protein's malfunction is linked to Dyskeratosis congenita, autosomal recessive, 1, a rare disorder characterized by bone marrow failure and other systemic manifestations. Understanding the role of H/ACA ribonucleoprotein complex subunit 3 could open doors to potential therapeutic strategies for this condition.